Can 29kDa rhGM-CSF expressed by silkworm pupae bioreactor bring into effect as active cytokine through orally administration?

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Yaozhou ZhangXiangfu Wu

Abstract

In order to study the effect of human granulocyte-macrophage colony-stimulating factor (hGM-CSF) as active cytokine through orally administration, we expressed hGM-CSF within silkworm pupae bioreactor. The purified rhGM-CSF named as BmrhGM-CSF is characterized as 29kDa glycoprotein, and its biological activity was measured both in vitro and in vivo. We found out BmrhGM-CSF could stimulate the colony formation of human bone marrow cells in a dose-dependent manner whether which were treated with or without gamma-ray 24h before. The ability of colony formation induced by BmrhGM-CSF is negatively correlated with gamma-ray intensity. As soon as 15min post oral administration with BmrhGM-CSF labeled with (125)I, an approximately 20kDa protein fragment was detected within mice blood by SDS-PAGE followed by autoradiography. In blood sample of test mice, a protein was also recognized by anti-hGM-CSF antibody using ELISA. The immunohistochemical analysis showed that BmrhGM-CSF was detected within intestinal histiocyte. This indicated it might be absorbed into blood via intestinal microvillus. Pharmacokinetics analysis after orally administered BmrhGM-CSF in animal model of leucopenia including mice, Beagle dogs and macaques showed that: ...Continue Reading

References

Mar 1, 1975·The Journal of Clinical Investigation·F W Ruscetti, P A Chervenick
May 1, 1994·Bioscience, Biotechnology, and Biochemistry·Y SaitoS Imayasu
Apr 4, 2000·Insect Biochemistry and Molecular Biology·K ShiraiH Iwamoto
May 9, 2001·Biochimica Et Biophysica Acta·Q HuangJ C Reed
Jul 20, 2002·Biochemical and Biophysical Research Communications·Won Jong RheeTai Hyun Park
Sep 25, 2003·Insect Biochemistry and Molecular Biology·Binita Shrivastava, Ananta Kumar Ghosh
Mar 20, 2004·The Journal of Veterinary Medical Science·Ken-ichiro HayashidaEtsumori Harada
Jul 5, 2005·Journal of Biotechnology·Tao LiuXiang-Fu Wu

❮ Previous
Next ❯

Citations

Jun 17, 2009·Functional & Integrative Genomics·Yaozhou ZhangXiangfu Wu
Apr 16, 2010·Applied Biochemistry and Biotechnology·Soledad ChazarraJosé Neptuno Rodríguez-López
Feb 26, 2013·Applied Biochemistry and Biotechnology·Fang ZhouZuoming Nie
Feb 4, 2010·The American Journal of Chinese Medicine·Hyo-Jung YangYoung-Kug Choo
Jun 21, 2012·Gene·Lancui YangZuoming Nie
Mar 27, 2010·Journal of Biomedicine & Biotechnology·Hanglian LanYaozhou Zhang
Jun 20, 2013·International Journal of Genomics·Zhengbing LvYaozhou Zhang
Apr 30, 2015·PloS One·Renuka SubramaniamHomayoun Shams
Dec 19, 2014·Molecular BioSystems·Francisco Ferreira Duarte JuniorMaria Aparecida Fernandez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.